Adrenal insufficiency of patients with graft versus host disease treated with extracorporeal photopheresis. (13th June 2019)

• Record Type: Journal Article
• Authors: Rushton, Cherie; Bacon, Elizabeth; Jennings, Emma; Marchetti, Paula; Alfred, Arun
• Is Part Of: British journal of nursing. Volume 28:Number 11(2019)
• Page Start: 698
• Page End: 701
• Publication Date: 2019-06-13
• Subjects: Extracorporeal photopheresis -- Graft versus host disease -- Adrenal insufficiency -- ACTH stimulation test; Nursing -- Periodicals; 610.73
• DOI: 10.12968/bjon.2019.28.11.698
• Languages: English
• ISSNs: 0966-0461

Abstract

Abstract : Graft versus host disease (GvHD) is a serious and common complication of allogenic haematopoietic stem cell transplant. Corticosteroids are considered the standard care for initial treatment of GvHD but a significant proportion of patients will need long-term steroid treatment for control of GvHD. Extracorporeal photopheresis (ECP) is a cell-based immunomodulatory therapy that is an accepted second line treatment in patients with steroid refractory, dependent or intolerant GvHD and has shown efficacy in allowing steroid dose reduction and discontinuation in this cohort of patients. Adrenal cortical insufficiency is defined by the inability of the adrenal cortex to produce sufficient amounts of glucocorticoids and/or mineralocorticoids leading to a severe and potentially life-threatening condition. The most common cause of drug-induced adrenal insufficiency is the suppression of the hypothalamic–pituitary–adrenal axis by exogenous glucocorticoid doses ≥5 mg prednisolone equivalent for more than 4 weeks. The aim of the study was to ascertain the number of patients with GvHD receiving ECP that are affected by adrenocortical insufficiency.